.avif)
.avif)
Apogee Therapeutics Email Format
Biotechnology Research
・
201-500 employees
・
Fully Remote, USA
Apogee Therapeutics is a biotechnology company developing novel therapies to address immunological and inflammatory disorders for patients worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@apogeetherapeutics.com
Company Overview
Industry
Biotechnology Research
Founded
2022
Headquarters
Fully Remote, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Key Executives
Michael Henderson, M.D. (Chief Executive Officer), Jane Pritchett Henderson (Chief Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Apogee Therapeutics?
Apogee Therapeutics uses the first.last format on apogeetherapeutics.com, so Jane Smith would be jane.smith@apogeetherapeutics.com.
What disease areas does Apogee Therapeutics focus on?
Apogee Therapeutics is a clinical-stage biotechnology company focused on inflammatory and immunological diseases, with programs targeting atopic dermatitis, asthma, eosinophilic esophagitis, and several other large indications in the I&I space.
How far along is Apogee Therapeutics' lead program, zumilokibart?
Zumilokibart, also known as APG777, has completed Phase 2 with positive 16-week data in atopic dermatitis and is on track for Phase 3 initiation in the second half of 2026. Apogee Therapeutics secured up to $1.3 billion in financing from Blackstone Life Sciences to support that development.
When was Apogee Therapeutics founded and who leads the company?
Apogee Therapeutics was founded in 2022 and is led by Michael Henderson, M.D. as Chief Executive Officer, with Jane Pritchett Henderson serving as Chief Financial Officer. You can use Clay to quickly surface verified contact details for the leadership team.
Does Apogee Therapeutics have any combination antibody programs beyond its lead asset?
Yes, Apogee Therapeutics is advancing two combination programs: APG279, which pairs zumilokibart with APG990 targeting OX40L for atopic dermatitis, and APG273, which combines zumilokibart with APG333 targeting TSLP for asthma and COPD.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating